Citations

Clear

1053 citation(s) found for "Andre, F".

The learning curve of single‐port extraperitoneal robotic radical prostatectomy: Initial experience and outcomes from a newly graduated fellowship‐trained robotic surgeon
Hershenhouse, Jacob , Kim, S., Gevorkyan, Rafael, Hom, Brian , Eppler, Michael , Ford, Patrick, Pathak, Ram, Autorino, Riccardo, Badani, Ketan K., Crivellaro, Simone, Hemal, Sij, Autorino, Riccardo , Hershenhouse, Jacob S , Autorino, Riccardo , Badani, Ketan K , Abreu, Andre Luis , Badani, Ketan K. , Crivellaro, Simone

Mayo Clinic

BJUI Compass | March 11, 2026 | Volume: 7 | Issue: 3 | Pages: No page available

10.1002/bco2.70184 | PMID 41822202 Get It

Abstract Introduction and Objective This study aims to evaluate the learning curve and perioperative outcomes of single‐port extraperitoneal robotic radical prostatectomy (SP‐EP‐RARP) performed by a single surgeon at a high‐volume academic institution. Methods A retrospective review of a prospectively maintained database was conducted for patients who underwent SP‐EP‐RARP from September 2023 to August 2025. Key metrics included operative time, estimated blood loss, conversion rate, nerve‐sparing status, pathological margin status and continence (0–1 pad for safety), and 30‐day complication rate. Descriptive statistics were used, and outcomes were analysed chronologically to assess for trends suggesting a learning curve. Results The cohort included 53 patients who underwent extraperitoneal SP‐EP‐RARP. Median operative time was 213 min (IQR: 145–281). Median estimated blood loss was 100 mL (IQR: 75–125). Nerve‐sparing was attempted in 75.5% of cases. No assist or plus one ports were utilized. Final pathology revealed pT2 disease in 64.1% (34 cases), pT3a in 32.1% (17 cases) and pT3b in 3.7% (2 cases). Overall positive margin rate was 26.4%. Thirty‐day Clavien–Dindo Grades I–II complication rates were 11.3%, and no major complications or 90‐day complications were reported. Continence rates at 6 weeks, 3 months and 6 months were 72%, 72% and 75%, respectively. Stabilization of operative times and intraoperative outcomes occurred after approximately 25–30 cases. Conclusion SP‐EP‐RARP can be safely implemented by a newly graduated fellowship‐trained robotic surgeon with acceptable oncologic and functional outcomes. Initial learning can be estimated at approximately 25–30 cases.
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Crowell, Cameron , Mankuzhy, Nikhil P. , Bennett, Julie , Bandopadhayay, Pratiti , Sturm, D., Green, Adam L. , Gupta, Tejpal , Chatterjee, Abhishek , Epari, Sridhar , Chinnaswamy, G., Prasad, Maya , Patel, Sonal, MacNeil, Mary , Vanan, Magimairajan , Larouche, Valérie , Renzi, Samuele , Jones, Jacquelyn , Perreault, Sébastien , Mata-Mbemba, Daddy , Sangatsuda, Yuhei , Yoshimoto, Koji , Lin, Emily , Feddersen, Charlotte R., Pavon-Mengual, Miriam, Vizzini, Olivia, Zápotocký, Michal, Popovacki, Aimee, Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L., Satgunaseelan, Laveniya, Williams, Andrew , Yao, Kristin, Ronsley, Rebecca , Cheng, Sylvia, Eisenstat, David, Andre, N., Matheson, K., Chan, Aimee , Lim-Fat, Mary Jane, Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila, Khan, Sara , Salloum, Ralph , Galvin, Robert , Hawkins, Cynthia, Karajannis, Matthias A. , Jones, David T.W., Ligon, K. L., Jabado, Nada, Erker, Craig , Sturm, Dominik , Chinnaswamy, Girish , Patel, Sohil H , Vanan, Magimairajan Issai , Feddersen, Charlotte , Cruz, Ofelia , Pavon-Mengual, Miriam , Vizzini, Olivia , Zápotocký, Michal , Popovacki, Aimee , Klawinski, Darren , Hansford, Jordan R , Schlosser, Mary-Pat , Omene, Egiroh , Alexander, Kimberley L , Satgunaseelan, Laveniya , Williams, Andrew , Yao, Kristin , Ronsley, Rebecca , Cheng, Sylvia , Ludlow, Louise , Eisenstat, David , Khuong-Quang, Dong-Anh , Tabouret, Emeline , André, Nicolas , Matheson, Kara , Chan, Aimee , Lim-Fat, Mary Jane , Lapointe, Sarah , Cayrol, Romain , Coleman, Christina , Juretic, Nikoleta , McThenia, Sheila , Khan, Sara , Wright-Nadkarni, Mariah , Salloum, Ralph , Galvin, Robert T , Sener, Ugur , Hawkins, Cynthia , Imber, Brandon S , Karajannis, Matthias A , Jones, David T W , Ligon, Keith L , Jabado, Nada , Erker, Craig , Larouche, Valérie , Hansford, Jordan R. , Satgunaseelan, Laveniya , Sener, Uğur , Hawkins, Cynthia

Mayo Clinic

Clinical Cancer Research | March 9, 2026 | Volume: 32 | Issue: 11 | Pages: 2243-2254

10.1158/1078-0432.ccr-25-3764 | PMID 41801141 Get It

Abstract Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis. Experimental Design: This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets. Results: A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97). Conclusions: This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
The Utility of Automated, Data-Driven Clinical Support in Telemedicine for Critical Illness: A Survey-Based Study
HOLDER, ANDRE, Winterbottom, Fiona , Kosmisky, Desiree , Raikhelkar, Jayashree , Ahmed, Ahmed Sayed , Mahmoud, Mohamed A., Ahmed, Ahmed S, Laudański, Krzysztof , Sayed Ahmed, Ahmed , Mahmoud, Mohamed A.

Mayo Clinic

Critical Care Explorations | February 25, 2026 | Volume: 8 | Issue: 3 | Pages: e1374

10.1097/cce.0000000000001374 | PMID 41738600 Get It

A growing number of data-driven clinical decision support (CDS) tools are incorporated into tele-critical care, but the clinician perceptions of their utility are largely unknown. The objective of this web-based survey study was to understand the perceived utility of data-driven CDS in tele-critical care. The survey had 158 respondents (1.1% response rate), with 51.3% stating they currently use a data-driven CDS tool. Of those who responded about the impact of data-driven CDS, most (62.0%) reported a meaningful impact on workup, evidence-based care, or patient outcomes. Survey participants found CDS most useful if they or their colleagues had positive experiences with it, especially if it was responsible for improved patient outcomes. Thus, data-driven CDS is perceived useful for tele-critical care services.
Early mortality with bispecific antibody therapy in RRMM: an IMWG immunotherapy database real-world analysis
Tan, Carlyn Rose, Usmani, Saad Z., Derkach, Andriy , Corraes, Andre De Menezes Silva, Parrondo, Ricardo , Ailawadhi, S., Asoori, Sireesha, Dave, Mrugakshi, Popat, Rakesh, Morjaria, Oliver, Hajek, Roman , Htut, Myo , Kastritis, Efstathios, Dimopoulos, M A, Martínez-López, Joaquín, Nagarajan, Chandramouli, Bal, Susan, Costa, Luciano J., Einsele, Hermann, Steinbrunn, Torsten, Riedhammer, Christine , Banerjee, Rahul, Chng, Wee Joo, Tso, Allison CY, Lin, Yi, Martin, Tom, Mian, Hira, Martínez‐López, Joaquín , Mian, Hira , Tan, Carlyn R , de Meneze Silva Corraes, Andre, Mihalyova, Jana , Visram, Alissa , Kastritis, Efstathios , Martinez-Lopez, Joaquin , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J , Waldschmidt, Johannes M , Banerjee, Rahul , Tso, Allison , Martin, Thomas , Mian, Hira , Parrondo, Ricardo D , Derkach, Andriy , Usmani, Saad Z. , Corraes, Andre De Menezes Silva , Ailawadhi, Sikander , Popat, Rakesh , Hájek, Roman , Janakiram, Murali , Visram, Alissa , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Nagarajan, Chandramouli , Bal, Susan , Costa, Luciano J. , Steinbrunn, Torsten , Banerjee, Rahul , Chng, Wee Joo

Mayo Clinic

Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 2937-2946

10.1182/bloodadvances.2025019231 | PMID 41734378 Get It

Abstract Recent therapeutic advances, including bispecific antibodies (bsAbs), have improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM). However, early mortality (EM) remains a significant challenge, even in the era of novel immunotherapies. We conducted a multicenter, retrospective analysis of real-world patients with RRMM treated with commercial bsAbs to evaluate the incidence and causes of EM. Between May 2022 and June 2025, a total of 441 patients were treated across 7 countries. EM, defined as death within 12 months of therapy initiation, occurred in 148 patients (34%), with a median time from bsAb initiation to death of 2.87 months (interquartile range, 1.38-6.85). The leading cause of EM was progressive disease (72%), followed by infection (13%); regardless of the cause of death, 82% had active disease at the time of death. Our findings highlight that despite encouraging efficacy, EM remains high among real-world bsAb recipients, emphasizing the need for improved disease control strategies and supportive care interventions.
Abstract PS1-04-18: Identifying Smoking-Related Factors in Breast Cancer Patients: Mayo Clinic Registry Insight
Vierkant, R. A., Larson, N. L., D’Andre, S. D., Couch, F. J., Olson, J. E., Ruddy, K. J., Hirani, Samina , Vierkant, Robert A., D’Andre, Stacy D. , Couch, F.J., Ruddy, KJ

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS1-04-18-PS1-04-18

10.1158/1557-3265.sabcs25-ps1-04-18 Get It

Abstract Background: Smoking, a known risk factor for numerous cancers, negatively impacts long-term survival in breast cancer (BC) survivors (Parada H Jr et al., 2017; Pierce et al., 2019). This study aims to characterize baseline smoking behaviors among breast cancer patients who self-reported smoking during an initial survey. Objectives: To assess attributes of patients self-reporting as current smokers near BC diagnosis, examining demographics, habits, quality of life, cancer treatments, comorbidities, and finances. Methods: Patients with newly diagnosed BC seen at Mayo Clinic Rochester between 2014-2024 were invited to enroll in the Mayo Clinic Breast Disease Registry. Consenting participants who completed self-reported questionnaires at baseline were included in this study. Smoking status and related variables at the time of survey completion were assessed via a baseline questionnaire, classifying participants as current, former, or never smokers. Of 3,959 participants completing baseline surveys, 3,729 were analyzed after excluding 103 with missing smoking data and 127 with their baseline survey returned >1-year post-diagnosis. Categorical variables were summarized with frequencies and percents, continuous variables with distributional statistics. Univariable associations with current smoking were assessed via two-sample t-tests (continuous) and chi-square or Fisher exact tests (categorical). Significant variables (p<0.05) were included in a multivariable logistic regression model. Results: Among 3,729 BC patients (mean age 58.3 years, SD 12.9), 99.1% were female, 97.1% White, and 98.7% non-Hispanic. Only 2.7% reported financial difficulty, 56.4% had a bachelor's degree or higher, 81.7% were married or equivalent, and 21.7% consumed ≥5 alcoholic drinks/week. Tumor stage distribution was as follows: Stage 0 (13.9%), Stage 1 (43.9%), Stage 2 (28.9%), Stage 3 (8.9%), and Stage 4 (4.5%); 33.8% received chemotherapy, 56.5% radiotherapy, 63.6% endocrine therapy, and 42.2% underwent mastectomy. Current smokers (2.6%, n = 95) had a median diagnosis age of 59.1 (IQR 31.8-87.1),with 32.6% consuming ≥5 drinks/week (vs. 21.5% in non-smokers, univariable p = 0.012), 69.5% with less than a Bachelor’s degree (vs. 42.9%, p<0.001), 9.6% facing financial difficulty (vs. 2.5%, p<0.001), and 10.5% diagnosed within 270-365 days after survey return (vs. 4.2%, p = 0.022). Tumor stage showed 47% with Stage 1 (vs. 43.7%, p = 0.245); 33.7% received chemotherapy, 60.0% radiotherapy, and 58.9% endocrine therapy. Current smokers had a mean smoking initiation age of 19.9 (SD 6.2), smoked 12.5 cigarettes/day (SD 7.9) for 32.8 years (SD 14.1), with mean 22.3 pack-years (SD 17.2).Univariable associations of demographic and clinical characteristics with current smoking showed Compared to never or former smokers, current smokers at the time of survey took a longer time to return their baseline survey (p = 0.022), were more likely to consume five or more alcoholic drinks per week (p = 0.012), were more likely to have difficulty paying their bills (p<0.001) and were less likely to obtain a Bachelor's degree or higher (p<0.001). These associations remained significant after multivariable adjustment. Conclusion: Current smoking (2.6%) soon after a BC diagnosis was independently associated with delayed survey return, higher alcohol use, financial difficulty, and lower education. Assessing smoking status and referring patients to smoking cessation programs are critical for addressing these risk factors and improving health outcomes. These findings highlight distinct socioeconomic and behavioral profiles among current smokers, suggesting potential targets for tailored interventions. Citation Format: S. Hirani, R. A. Vierkant, N. L. Larson, S. D. D’Andre, F. J. Couch, J. E. Olson, K. J. Ruddy. Identifying Smoking-Related Factors in Breast Cancer Patients: Mayo Clinic Registry Insight [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS1-04-18.